US · BRNS
Barinthus Biotherapeutics plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- Didcot OX11 0DF
- Website
- barinthusbio.com
Price · as of 2024-12-31
$0.65
Market cap 23.85M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $255.63 | +39,185.38% |
| Intrinsic Value(DCF) | $1.01 | +55.22% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $45.21 | |||
| 2021 | $5.26 | $28.42 | $4.96 | $0.00 | $112.38 |
| 2022 | $2.61 | $2,552.77 | $4.21 | $6.91 | $2,275.66 |
| 2023 | $2.60 | $59.77 | $2.05 | $0.00 | $163.94 |
| 2024 | $0.99 | $255.63 | $0.70 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Barinthus Biotherapeutics plc's (BRNS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $255.63
- Current price
- $0.65
- AI upside
- +39,185.38%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.01
+55.22% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BRNS | Barinthus Biotherapeutics… | $0.65 | 23.85M | +39,185% | +55% | — | — | -0.63 | 0.30 | 2.59 | 1.08 | — | 0.36 | 100.00% | -454.07% | -408.00% | -38.62% | -152.56% | -32.65% | 0.09 | -1282.45 | 8.03 | 7.90 | 1.78 | -1885.00% | 176646.00% | -4705.00% | -76.97% | -1.85 | -67.01% | 0.00% | 0.00% | 0.00% | 0.88 | 2.01 | -4.00 | -1.79 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| KPTI | Karyopharm Therapeutics I… | $9.41 | 80.34M | +75% | -59% | — | — | -0.53 | -0.36 | 0.72 | -3.04 | -0.59 | -0.36 | 95.93% | -62.10% | -134.21% | 81.86% | 81.25% | -143.71% | -0.80 | -1.98 | 1.12 | 0.98 | -1.91 | 9054.00% | 57.00% | -4095.00% | -71.87% | -0.82 | 67.51% | 0.00% | 0.00% | 0.00% | -3.03 | -3.65 | 1.88 | -23.86 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| OKUR | OnKure Therapeutics, Inc. | $2.71 | 36.72M | — | — | — | — | -1.27 | 0.64 | — | 0.83 | -2.59 | 0.64 | 0.00% | — | — | -5304.43% | 79.46% | -69.93% | 0.01 | -181.29 | 10.73 | 10.52 | 2.12 | 4906.00% | — | 4707.00% | -76.41% | -4.85 | 74.76% | 0.00% | 0.00% | 120.18% | 0.79 | 0.83 | — | 1.25 |
| SNTI | Senti Biosciences, Inc. | $0.94 | 24.82M | +2,578% | — | — | — | -0.31 | 0.63 | — | -0.03 | — | 0.63 | 0.00% | — | — | -114.06% | -153.24% | -48.58% | 1.31 | — | 4.49 | 3.81 | 0.27 | -4513.00% | -10000.00% | -3571.00% | -256.05% | -3.15 | -103.99% | 0.00% | 0.00% | 101.22% | -0.03 | -0.04 | — | -5.61 |
| TPST | Tempest Therapeutics, Inc… | $2.28 | 11.23M | — | — | — | — | -7.25 | 15.85 | — | -7.18 | — | 15.85 | 0.00% | — | — | -182.35% | -676.64% | -89.90% | 0.80 | -31.93 | 2.21 | 2.13 | 0.37 | -2147.00% | — | 2156.00% | -11.03% | -2.32 | -538.75% | 0.00% | 0.00% | 0.00% | -6.86 | -8.62 | — | -1.70 |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
- CEO
- William J. Enright
- Employees
- 105
- Beta
- -0.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.01 ÷ $0.65) − 1 = +55.22% (DCF, example).